Tissue matrices comprising placental stem cells, and methods of making the same
AssigneeAnthrogenesis Corporation
InventorRobert J. Hariri
Life of this patent
Estimating the term…
Abstract
A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
Claims55
A method of preparing a tissue matrix, comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood, and comprise stem cells that are CD34− or OCT-4+, wherein said placental stem cells are SSEA4−.
A decellularized or synthetic tissue matrix comprising human placental stem cells that are CD34− or OCT-4+, wherein said placental stem cells are SSEA4−.
A tissue comprising a decellularized organ and a plurality of CD34− or OCT-4+ human placental stem cells, wherein said placental stem cells are SSEA4−.
A method of producing a tissue comprising contacting a decellularized organ with a plurality of CD34− or OCT-4+ human placental stem cells, wherein said placental stem cells are SSEA4−.
A method of transplanting a tissue into a recipient, comprising transplanting said tissue into a recipient, wherein said tissue comprises a decellularized organ and a plurality of CD34− or OCT-4+ human placental stem cells, wherein said placental stem cells are SSEA4−, and wherein said placental stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood.
A tissue matrix comprising isolated CD34−, CD10+, SH2+ multipotent placental cells.
A tissue matrix comprising isolated human multipotent placental cells, wherein said placental stem cells are CD29+, CD90+, SH2+, SH3+, SH4+, CD34−, and CD45−.
Dependencies are inferred from the claim text.